Impact Factor
4.62
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
8.83
3,537 total citations
h5-index
70
h5 depth signal
Cited share
90.9%
380 of 418
Total citations
3,537
Citation footprint
Metric signal
8.94
External metric anchor
Self-citation
3.1%
109 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,015
Germany
221
China
216
Italy
206
France
181
Citing Fields of Research
Hematology
1,034
Lymphomas
975
Immunology
239
Oncology
132
Auto-Inflammatory Disorders
50
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,233
Articles tracked across the journal lifetime
Indexed publication set
418
380 cited publications
Last 12 months
264
22.0 publications/month
Open access share
100.0%
264 OA publications in the last year
Leading citing country
United States
1,015 citing publications
Leading citing field
Hematology
1,034 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v4, 2014-
v1, 2011-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lymphomas
Hematology
Broad Categories
Allergy and Immunology
Hematology
Neoplasms
Lymphomas
MeSH Descriptors
Hematologic Neoplasms.
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
03
04
DOI 10.1038/s41408-026-01648-y
Open DOI
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras
05
06
DOI 10.1038/s41408-026-01639-z
Open DOI
Targeting FcRL5 in multiple myeloma: biological rationale and strategic sequencing beyond BCMA and GPRC5D
07
DOI 10.1038/s41408-026-01630-8
Open DOI
The GMALL B ALL/NHL 2002 protocol yields high rates of durable response in high grade B cell lymphoma
08
09
DOI 10.1038/s41408-026-01645-1
Open DOI
Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies
10
DOI 10.1038/s41408-026-01632-6
Open DOI
SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models
Bibliographical & Catalog Notes
Articles added as received to annual volume in progress.